Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 11, 2002 - Issue 7
Submit an article Journal homepage
92
Views
7
CrossRef citations to date
0
Altmetric
Miscellaneous

Rheumatoid arthritis: developing pharmacological therapies

Larry W Moreland 1717 6th Ave. S., Rm. 068, Birmingham, AL, 35294-7201, UK, Tel: +1 205 934 7727; Fax: +1 205 975 5554;, E-mail: [email protected]
&
Richard J Misischia 1717 6th Ave. S., Rm. 068, Birmingham, AL, 35294-7201, UK, Tel: +1 205 934 7727; Fax: +1 205 975 5554;, E-mail: [email protected]
Pages 927-935 | Published online: 24 Feb 2005

Bibliography

  • MORELAND L: Inhibitors of tumor necrosis factor for rheumatoid arthritis. Rheumatol (1999) 26\(Suppl. 57):7–15.
  • ALARCON G: Epidemiology of rheumatoid arthritis. Rheum. Dis. Clio. North Am. (1995) 21:589–604.
  • AREND W, DAYER J: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. (1990) 33:305–315.
  • BRENNAN F, MAINI R, FELDMANN M: Cytokine expression in chronic inflammatory disease. Br. Med. Bull. (1995) 51:368–384.
  • BAND OLATO R, OPPENHEIM J: Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Sernin. Arthritis Rheum. (1996) 26:526–538.
  • STARKEBAUM G: Role of cytokines in rheumatoid arthritis. Sci. Med. (1998) Marl Apr:6–15.
  • MOSS M, JIN S, BECHERER J et al.: Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). Neuroimmunol (1997) 72:127–129.
  • BRENNAN F, FELDMANN M: Cytokines in autoimmunity. Carr: Opin. Immunol (1992) 4:754–759.
  • TARTAGLIA L, WEBER R, FIGARI I et al.: The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA (1991) 88:9292–9296.
  • AREND W, DAYER J: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. (1995) 38:151–160.
  • MORELAND L, MARGOLIES G, HECK Li et al.: Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. Rheumatol (1996) 23: 1849-1855.
  • WEINBLATT M, KREMER J, BANKHURST A et al: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N EngL J. Med. (1999) 340:253–259.
  • BATHON J, MARTIN R, FLEISCHMANN R et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl. I Med. (2000) 343:1586–1593.
  • ••Trial showing significant reduction in jointerosions with etanercept when compared to methotrexate.
  • MORELAND L, BAUMGARTNER S, SCHIFF M et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein. N Engl. Med (1997) 337:141–147.
  • MORELAND L, SCHIFF M, BAUMGARTNER S et al.: Etanercept therapy in rheumatoid arthritis. A randomised, controlled trial. Ann. Intern. Med. (1999) 130:478–486.
  • ROBINSON W, GENOVESE M, MORELAND L: Demyelinating and neurologic events reported in association with tumor necrosis factor-alpha antagonism: by what mechanisms could tumor necrosis factor-alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum. (2001) 44:1977–1983.
  • •Describes neurological adverse events associated with anti-TNF agents.
  • MOHAN N, EDWARDS E, CUPPS T et al.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. (2001) 44:2862–2869.
  • SHAKOOR N, MICHALSKA M, HARRIS C, BLOCK J: Drug-induced systemic lupus erythematosis. Lancet (2002) 359:579–580.
  • BRION PH, MITTAL-HENKLE A, KALUNIAN KC: Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann. Intern. Med. (1999) 131:634.
  • GALARIA NA, WERTH VP, SCHUMACHER HR: Leukocytoclastic vasculitis due to etanercept. Rheumatol (2000) 27:2041–2044.
  • McCAIN ME, QUINET RJ, DAVIS WE:Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (2002) 41:116–117.
  • ELLIOTT M, MAINI R, FELDMANN R et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. (1993) 36:1681–1690.
  • ••First trial of infliximab in DMARD-refractory RA patients.
  • ELLIOTT M, MAINI R, FELDMANN R et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumouir necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105–1110.
  • MAINI R, BREEDVELD F, KALDEN J et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1552–1563.
  • ••The first trial showing efficacy of inflixirnabin combination with methotrexate.
  • MAINI R, ST. CLAIRE, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concommitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet (1999) 354:1932–1939.
  • VAN OOSTEN BW, BARKHOF F, TRUYEN L et al.: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology(1996) 47:1531–1534.
  • CHARLES P, SMEENK R, DE JONG J et al.: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor-alpha: findings in open-label and randomised placebo-controlled trials. Arthritic Rheum. (2000) 43:2383–2390.
  • KAVANAUGH A: Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum. Dis. Clin. North Am. (1998) 24:593–614.
  • KEMPENI J: Preliminary results of early clinical trials with the fully human anti-TNF alpha monoclonal antibody D2E7. Ann. Rheum. Dis.(1999) 58:170–172.
  • KEYSTONE E, WEINBLATT M, FURST D et al.: The Armada Trial: A double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate (MTX). Arthritic Rheum. (2001) 44:S213.
  • VAN DE PUTTE L, RAU R, BREEDVELD F et al.: Efficacy of the fully human anti-TNE antibody D2E7 in rheumatoid arthritis. Arthritic Rheum. (1999) 42:S400.
  • RAU R, HERBORN G, SANDER 0 et al.: Long-term treatment with the fully human anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis. Arthritic Rheum. (1999) 42:S400.
  • MCCOMB J, GOULD T, CHLIPALA E et al.: Antiarthritic activity of soluble tumor necrosis factor receptorType I forms in adjuvant arthritis: correlation of plasma levels with efficacy. J. Rheumatol (1999) 26:1347–1351.
  • CALDWELL J, DAVIS M, JELECA-MAXWELL K et al.: A Phase I study of PEGylated soluble tumor necrosis factor receptor Type I (PEG sTNF-RI[p55])in subjects with rheumatoid arthritis (RA). Arthritic Rheum. (1999) 42:S236.
  • DAVIS M, FRAZIER J, MARTIN S, EDWARDS CI: Non-immunogenicity of a PEGylated soluble tumor necrosis factor receptor Type I (PEG sTNF-RI [p55]). Arthritic Rheum. (1999) 42:S77.
  • HAMMERMAN D: Clinical implications of osteoarthritis and aging. Ann. Rheum. Dis (1994) 30:82–85.
  • CHARLESON S, CARTWRIGHT M, FRANK J: Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology (1996) 111:445–454.
  • BROOKS P, EMERY P, EVANS J et al.: Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (1999) 38:779–788.
  • HERNANDEZ-DIAZ S, GARCIA RODRIGUEZ L: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding and perforation: an overview of epidemiological studies published in the 1990s. Arch. Intern. Med. (2000) 160:2093–2099.
  • HERNANDEZ-DIAZ S, GARCIA RODRIGUEZ L: Epidemiological assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am. J. Med. (2001) 110:S20–S27.
  • GRIFFIN M, YARED A, RAY W: Nonsteroidal anti-inflammatory drugs and acute renal failure in elderly persons. Am. J. Epidemiol (2000) 151:488–496.
  • PATRONO C, DUNN M: The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int. (1987) 32:1–12.
  • WHELTON A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Am. J. Med. (1999) 106:13–24.
  • LAINE L, HARPERS, SIMON T et al: Arandomised trial comparing the effect of rofecoxib, a cyclooxygenase-2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology (1999) 117:776–783.
  • HAWKEY C, LAINE L, SIMON T et al.: Comparison of the effect of rofecoxib ( a cyclooxyenase-2 inhibitor), ibuprofen, and placebo on the gastrointestinal mucosa of patients with osteoarthritis: a randomised, double-blind, placebo-controlled trial. Arthritic Rheum. (2000) 43:370–377.
  • GOLDSTEIN J, CORREA P, ZHAO W et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am. J. Gastroenterol (2001) 96:1019–1027.
  • WARNER T, GIULIANO F, VOJNOVIC I et al.: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA (1999) 96:7563–7568.
  • RIENDEAU D, CHARLES ON S, CROMLISH W et al.: Comparison of the cyclooxygenase-1 properties of nonsteroidal anti-inflammatory drugs (NSAIDS) and selective cyclooxygenase-2 inhibitors, using sensitive microsomal and platelet assays. Can. Physiol Pharmacol (1997) 75:1088–1095.
  • Pharmacia Corporation. Celebrex package insert. (1999).
  • SILVERSTEIN F, FAICH G, GOLDSTEIN J et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA (2000) 284:1247–1255.
  • ••Large, randomised trial comparinggastrointestinal effects of celecoxib and non-selective NSAIDs.
  • BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl. I Med. (2000) 343:1520–1528.
  • ••Large, randomised trial demonstratinglower incidence of upper gastrointestinal events with rofecoxib when compared to naproxen.
  • Pharmacia Corporation. Bextra package insert. (2002).
  • RIENDEAU D, PERCIVAL M, BRIDEAU C et al.: Etoricwdb (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. Pharmacol Exp. Thei: (2001) 296:558–566.
  • WHELTON A, MAURATH C, VERBURG K, GEIS G: Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am. J. Their (2000) 7:159–175.
  • WHELTON A: Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2 specific inhibitors. Am. J. Med. (2001) 110 (Suppl. 1):33–42.
  • HAMBERG M, SEVENSSON J, SAMUELSSON B: Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA (1975) 72:2294–2298.
  • CATELLA-LAWSON F, CROFFORD L: Cyclooxygenase inhibition and thrombogenicity. Am. J. Med. (2001) 110:S28–S32.
  • VAN HECKEN A, SCHWARTZ J, DEPRE M et al.: Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin. Pharmacol (2000) 40:1109–1120.
  • KNIJFF-DUTMER E, MARTENS A, VD LAAR M: Effects of nabumetone compared to naproxen on platelet aggregation in patients with rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58:257–259.
  • KUIPER S, JOOSTEN LA, BENDELE AM et al.: Different roles of tumor necrosis factor-alpha and interleukin-1 in murine streptococcal cell wall arthritis. Cytokine (1998) 10:690–702.
  • BRESNIHAN B, ALVARO-GARCIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41:2196–2204.
  • JIANG Y, GENANT HK, WATT Jet al: A multi-center, double-blind, dose-ranging, randomised, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritic Rheum. (2000) 43:1001–1009.
  • WATT I, COBBY M: Treatment of rheumatoid arthritis in patients with interleukin-1 receptor antagonist: radiographic assessment. &min. Arthritic Rheum. (2001) 30 (5 Suppl. 2):21–25.
  • COHEN S, HURD E, CUSH J et al: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritic Rheum. (2002) 46:614–624.
  • STORGARD C, STUPACK D, JONCZYK A, GOODMAN S, FOX R, CHERESH D: Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist.j Clin. Invest. (1999) 103:47–54.
  • PALEOLOG E: Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis. Ma Pathol (1997) 50:225–233.
  • HARTMAN G, DAGGAN M: Alpha(v)beta(3) Integrin antagonists as inhibitors of bone resorption. Expert Opin. Investig. Drugs. (2000) 9:1281–1291.
  • WANG A, WANG J, FISHER G, DIAMOND H: Interleuldn- 1 beta-stimulated invasion of articular cartilage by rheumatoid synovial fibroblasts is inhibited by antibodies to specific integrin receptors and by collagenase inhibitors. Arthritis Rheum. (1997) 40:1298–1307.
  • ELLIS C, KRUEGER G: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl. Merl (2001) 345:248–255.

Websites

  • htt//pada.gov/bbshopics/ANSWERS/ 192002/ ANS01145.html. FDA approves new indication and label changes for the arthritis drug, Vioxx. US Food and Drug Administration (2002). Accessed May 6, 2002.
  • http//vapbm.org/critoria/ lef. etan_infcriteria.pdf. Criteria for use of leflunomide, etanercept, and infliximab in the treatment of rheumatoid arthritis. US Food and Drug Administration; (2002). Available at: Accessed February 28, 2002.
  • •Compilation of adverse events reported with the use of inflizimab, etanercept and leflunomide.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.